Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.

Morris, J A

Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. [electronic resource] - Clinical transplantation Jun 2005 - 340-5 p. digital

Publication Type: Journal Article

0902-0063

10.1111/j.1399-0012.2005.00344.x doi


Adult
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Daclizumab
Female
Graft Rejection--prevention & control
Humans
Immunoglobulin G--therapeutic use
Immunosuppressive Agents--therapeutic use
Kidney Transplantation--immunology
Male
Middle Aged
Survival Analysis